CN102940677B - Medicine composition for treating diabetic foot - Google Patents
Medicine composition for treating diabetic foot Download PDFInfo
- Publication number
- CN102940677B CN102940677B CN201210428581.XA CN201210428581A CN102940677B CN 102940677 B CN102940677 B CN 102940677B CN 201210428581 A CN201210428581 A CN 201210428581A CN 102940677 B CN102940677 B CN 102940677B
- Authority
- CN
- China
- Prior art keywords
- parts
- diabetic foot
- medicine
- treatment
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 208000008960 Diabetic foot Diseases 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title claims description 21
- 241000660877 Coridius Species 0.000 claims abstract description 16
- 241001489978 Eupolyphaga Species 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 238000005469 granulation Methods 0.000 claims description 15
- 230000003179 granulation Effects 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 241001165494 Rhodiola Species 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 241000083902 Rhodiola sachalinensis Species 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 206010052428 Wound Diseases 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000012467 final product Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 238000002266 amputation Methods 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010040943 Skin Ulcer Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 231100000019 skin ulcer Toxicity 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010012665 Diabetic gangrene Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 208000033386 Buerger disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000005736 Nervous System Malformations Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a medicine composition for treating diabetic foot, comprising Rhodiola sachalinensis, Eupolyphaga, aspongopus and liquorice. The medicine composition disclosed herein has low price and no side effect.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of diabetes, relate to specifically a kind of pharmaceutical composition for the treatment of diabetic foot.
Background technology
Diabetes are that China's sickness rate is high, endanger one of serious epidemic diseases.According to statistics, the mortality rate of diabetic complication is only second to cardiovascular diseases, cerebrovascular and tumor, occupies the 4th.Diabetes mellitus in China patient quantity has approached 4,000 ten thousand people, occupies third place in the world, compares with 0.7% of the eighties in 20th century, has increased by 5 times.
Diabetics is because the concentration of glucose in blood is too high, human body defensive ability/resistance ability declines, the supply of blood flow of lower limb and foot is not enough, causes foot to resist the decline of infection and wound self-healing ability, once wound, ulcer and infection appear in foot or lower limb, as treatment not in time, often be difficult to healing, a slight wound will prolongedly not healed, and wound scope expands fast, even downright bad, the amputation of finally having to.
Diabetic foot is most commonly in long, the long-term bad middle-aged and elderly people of glycemic control of diabetes medical history, is one of diabetes severe complication, and sickness rate 15%～20%, is the main cause that amputation disables.It is numbness that the diabetic foot initial stage shows, send out cool, sensory capacity reduces, easily injured, shallow table wound is difficult for healing etc., often easily out in the cold, and later stage deterioration is very fast, probably in one week, faces amputation.
Therapeutic Method major control blood glucose, blood fat and the blood pressure of the diabetic foot of doctor trained in Western medicine aspect treatment at present, improve blood circulation, improves peripheral neuropathy, uses antibiotic anti-infective therapy, changing dressings of ulcer wound surface processed etc.Chemical drugs does not also have the special medicine for diabetic foot, and general treatment method is conservative symptomatic treatment, and conventional chemicals has obvious side effect simultaneously, and diabetics needs lifelong medication, and long-term prescription can exert an adverse impact to health.
Diabetic foot claims again diabetic gangrene, belongs to the traditional Chinese medical science " necrosis " category together with thromboangiitis obliterans, atherosclerotic occlusive disease.Chinese medicine thinks that this disease is mainly deficiency of both QI and YIN, obstruction of collaterals by blood stasis, QI and blood can not sensible extremity due to.Adopt the Chinese medicine of suiting the medicine to the illness can reduce patient's blood viscosity, increase LBF, remove the damage factor of blood capillary and local organization, make local blood for improving, be conducive to diabetic gangrene's recovery.Although Chinese medicine verification treatment diabetic foot has certain advantage, but there is no at present specially for diabetic foot, be used for the treatment of the Chinese patent medicine listing of diabetic foot, substantially just lean on doctor for the interim prescription of different patients, do not there is the general directive significance of clinical practice.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition diabetic foot, determined curative effect for the treatment of.This medicine composite for curing diabetic foot is with strong points, and curative effect is better, and side effect is little, and safety is good.
To achieve these goals, technical scheme provided by the invention is:
Treat a pharmaceutical composition for diabetic foot, it is to be the medicament that medicinal raw material is made by Radix Rhodiolae, eupolyphaga, Aspongopus and Radix Glycyrrhizae.
The weight proportion of pharmaceutical composition of the present invention medicine material used can be: Radix Rhodiolae 5-20 part, eupolyphaga 1-12 part, Aspongopus 1-6 part, Radix Glycyrrhizae 2-5 part.
More preferably the proportioning of pharmaceutical composition of the present invention medicine material used is: Radix Rhodiolae 8-15 part, eupolyphaga 4-8 part, Aspongopus 2-4 part, Radix Glycyrrhizae 1-3 part.
The best proportioning of pharmaceutical composition of the present invention medicine material used is: 12 parts of Radix Rhodiolaes, 6 parts of eupolyphaga, 3 parts of Aspongopuss, 2 parts, Radix Glycyrrhizae
The pharmaceutical composition of above-mentioned treatment diabetic foot can be made each crude drug after treatment according to conventional formulation method the medicine of any one dosage form suitable on pharmaceutics, preferably granulation agent, tablet, hard capsule, oral liquid, soft capsule, drop pill etc.
According to the needs of the various drug forms of preparation, medicine of the present invention also can add suitable pharmaceutic adjuvant in preparation process, as starch, dextrin, microcrystalline cellulose, amylum pregelatinisatum, magnesium stearate, micropowder silica gel, sucrose, carboxymethyl starch sodium etc.
Compared with prior art, the invention has the beneficial effects as follows: the present invention's various raw medicinal materials used are the Chinese crude drug that meets country or provincial standard regulation.The present invention treats in the pharmaceutical composition of diabetic foot, and Radix Rhodiolae is cold in nature, and sweet-puckery flavor is attributed to lung meridian, heart channel.Benefiting QI for activating blood circulation, promotes blood circulation and relievings asthma.Eupolyphaga salty in the mouth, cold in nature, return Liver Channel.Removing blood stasis, reunion of fractured tendons and bones.Aspongopus salty in the mouth, warm in nature, inducing diuresis for treating stranguria syndrome, promoting the circulation of QI to relieve pain, warming the kidney to invigorate YANG.The invigorating middle warmer of Radix Glycyrrhizae QI invigorating, the function of heat-clearing and toxic substances removing, the mediation property of medicine.Above 4 taste Chinese medicine composition application, have Synergistic function, are used for the treatment of diabetic foot, determined curative effect, through clinical research, show, it is better that medicine of the present invention is used for the treatment of diabetic foot curative effect, and total effective rate reaches more than 90%, can dwindle wound surface area, reduce amputation rate, shorten and treat the course for the treatment of.And do not find obvious side effect and untoward reaction.
The specific embodiment
Below in conjunction with the specific embodiment, the present invention is described in further detail.
Embodiment 1
The pharmaceutical composition of the treatment diabetic foot that the present embodiment is enumerated, is comprised of the medicinal raw material of following weight:
12 parts of Radix Rhodiolaes, 6 parts of eupolyphaga, 3 parts of Aspongopuss, 2 parts, Radix Glycyrrhizae.
Granulation agent as follows: get the crude drug of described proportioning, add respectively suitable quantity of water, adopt decocting method to extract respectively 2 times, filter, merge 2 times filtrate, by each concentrated solution mix homogeneously, dry after concentrating, after granulation, be distributed into bag and get final product.
Embodiment 2
The pharmaceutical composition of the treatment diabetic foot that the present embodiment is enumerated, is comprised of the medicinal raw material of following weight:
20 parts of Radix Rhodiolaes, 12 parts of eupolyphaga, 6 parts of Aspongopuss, 5 parts, Radix Glycyrrhizae.
Granulation agent as follows: get the crude drug of described proportioning, add respectively suitable quantity of water, adopt decocting method to extract respectively 3 times, filter, merge 3 times filtrate, by each concentrated solution mix homogeneously, dry after concentrating, after granulation, be distributed into bag and get final product.
Embodiment 3
The pharmaceutical composition of the treatment diabetic foot that the present embodiment is enumerated, is comprised of the medicinal raw material of following weight:
8 parts of Radix Rhodiolaes, 4 parts of eupolyphaga, 2 parts of Aspongopuss, 1 part, Radix Glycyrrhizae.
Granulation agent as follows: get the crude drug of described proportioning, add respectively appropriate 70% ethanol, adopt reflux extraction to extract respectively 3 times, filter, merge 3 times filtrate, reclaim ethanol and concentrate after by each concentrated solution mix homogeneously, dry, after granulation, be distributed into bag and get final product.
Embodiment 4
The pharmaceutical composition of the treatment diabetic foot that the present embodiment is enumerated, is comprised of the medicinal raw material of following weight:
5 parts of Radix Rhodiolaes, 1 part of eupolyphaga, 1 part of Aspongopus, 2 parts, Radix Glycyrrhizae.
Granulation agent as follows: get the crude drug of described proportioning, add respectively 80% ethanol of approximately 10 times of amounts, employing percolation extracts, filters, by each concentrated solution mix homogeneously, dry after recovery ethanol also concentrates, and is distributed into bag and get final product after granulation.
Embodiment 5
The pharmaceutical composition of the treatment diabetic foot that the present embodiment is enumerated, is comprised of the medicinal raw material of following weight:
15 parts of Radix Rhodiolaes, 8 parts of eupolyphaga, 4 parts of Aspongopuss, 3 parts, Radix Glycyrrhizae.
Granulation agent as follows: get the crude drug of described proportioning, mix, add suitable quantity of water, adopt decocting method to extract 3 times, filter, merge 3 times filtrate, concentrated, dry, after granulation, be distributed into bag and get final product.
Embodiment 6
The pharmaceutical composition of the treatment diabetic foot that the present embodiment is enumerated, is comprised of the medicinal raw material of following weight:
12 parts of Radix Rhodiolaes, 8 parts of eupolyphaga, 2 parts of Aspongopuss, 3 parts, Radix Glycyrrhizae.
Granulation agent as follows: get the crude drug of described proportioning, mix, add appropriate 65% ethanol, adopt reflux extraction to extract 2 times, filter, merge 2 times filtrate, concentrated, dry, after granulation, be distributed into bag and get final product.
Embodiment 7
The pharmaceutical composition of the treatment diabetic foot that the present embodiment is enumerated, is comprised of the medicinal raw material of following weight:
8 parts of Radix Rhodiolaes, 6 parts of eupolyphaga, 3 parts of Aspongopuss, 1 part, Radix Glycyrrhizae.
Make as follows tablet: get the crude drug of described proportioning, mix, add suitable quantity of water, adopt decocting method to extract 3 times, filter, merges 3 times filtrate, concentrated, dry, the rear tabletting and get final product of granulating.
Embodiment 8
The pharmaceutical composition of the treatment diabetic foot that the present embodiment is enumerated, is comprised of the medicinal raw material of following weight:
14 parts of Radix Rhodiolaes, 4 parts of eupolyphaga, 3 parts of Aspongopuss, 2 parts, Radix Glycyrrhizae.
Make as follows capsule: get the crude drug of described proportioning, mix, add suitable quantity of water, adopt decocting method to extract 2 times, filter, merge 2 times filtrate, concentrated, dry, after granulation, pack in hungry area softgel shell and get final product.
The various embodiments described above medicine, also can be according to other conventional formulation method, by each crude drug of corresponding weight proportion through other extract and the method processing such as purification after, make again the medicine of other dosage form, as: granule, tablet, hard capsule, oral liquid, soft capsule, drop pill, water pill, honeyed pill etc.
In addition, according to the needs of the various drug forms of preparation, the various embodiments described above medicine also can add suitable pharmaceutic adjuvant as magnesium stearate, starch, dextrin, sucrose, microcrystalline Cellulose, hydroxypropyl emthylcellulose, vegetable oil, lecithin, Polyethylene Glycol, propylene glycol, ethyl hydroxybenzoate etc. in preparation process.
For the efficacy and saferry of proof medicine of the present invention, inventor has carried out the clinical research of 100 examples.The research method and the result of the test that adopt are as follows:
The granule of medicine of the present invention for making according to crude drug component and the preparation method of embodiment 1.
Selection is diagnosed as patient's 100 examples of diabetic foot, through scheduling to last the objective clinical observation of system in March.Medicine group all cases of the present invention all meets the diagnostic criteria (draft) of the diabetic foot (acral necrosis) of first national diabetic foot academic conference formulation of Chinese Medical Association.Medicine group case man of the present invention 50 examples, female's 50 examples; Observe 3 months.
Method of administration: every day potion, minutes 3 times are oral.When taking medicine, coordinate following Therapeutic Method: 1. insulinize, makes glycemic control between 7～9mmol/L.2. concurrent infection person, gives antiinflammatory and symptomatic treatment.3. for suffering from sufficient wound surface, do corresponding processing.
Curative effect is sentenced standard: cure: wound surface all healed; Effective: to take a turn for the better two more than rank; Effective: to take a turn for the better 1 more than rank; Invalid: unchanged or gangrenous increasing the weight of.
Observation index comprises following aspect before taking medicine and after taking medicine:
(1) safety indexes: blood pressure, pulse, blood, urine, the large routine of excrement three and electrocardiogram, liver, kidney brake check.
(2) health giving quality index:
A. general curative effect comparison
B. skin ulcer face area, the product representation with greatest length (cm) * Breadth Maximum (cm), if any many places wound surface, records the gross area.
(3) untoward reaction is observed: comprise gastrointestinal reaction, nervous system abnormality, skin allergy etc.
All cases are all carried out efficacy determination after treating 3 months.Result: medicine group of the present invention is cured 40 examples, effective 38 examples, effective 14 examples, invalid 8 examples; Total effective rate 92%.Before treatment, skin ulcer face area is 23.54 ± 17.65, and after treatment, skin ulcer face area is 8.73 ± 5.41, and through paired data t check, P<0.01, has significant difference.In drug administration process, have no obvious adverse reaction, electrocardiogram before and after taking medicine, liver, renal function, blood, routine urinalysis are without significant change.
Claims (1)
1. a pharmaceutical composition for the treatment of diabetic foot, is characterized in that: it is to be the medicament that medicinal raw material is made by Radix Rhodiolae, eupolyphaga, Aspongopus and Radix Glycyrrhizae; The weight portion proportioning of described crude drug is 12 parts of Radix Rhodiolaes, 6 parts of eupolyphaga, 3 parts of Aspongopuss, 2 parts, Radix Glycyrrhizae; The preparation method of described pharmaceutical composition adds respectively suitable quantity of water for getting crude drug, adopts decocting method to extract respectively 2 times, filters, and merges 2 times filtrate, by each concentrated solution mix homogeneously, dry after concentrating, and is distributed into bag after granulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210428581.XA CN102940677B (en) | 2012-10-31 | 2012-10-31 | Medicine composition for treating diabetic foot |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210428581.XA CN102940677B (en) | 2012-10-31 | 2012-10-31 | Medicine composition for treating diabetic foot |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102940677A CN102940677A (en) | 2013-02-27 |
| CN102940677B true CN102940677B (en) | 2014-11-26 |
Family
ID=47723737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210428581.XA Expired - Fee Related CN102940677B (en) | 2012-10-31 | 2012-10-31 | Medicine composition for treating diabetic foot |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102940677B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104800425A (en) * | 2015-04-23 | 2015-07-29 | 杨孝良 | External Chinese herbal compound applying liquid for treating diabetic foot ulcer |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116327688A (en) * | 2023-04-04 | 2023-06-27 | 普联东俪(烟台)生物科技有限公司 | Stem cell gel for treating diabetic foot |
-
2012
- 2012-10-31 CN CN201210428581.XA patent/CN102940677B/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| 《诺迪康胶囊治疗糖尿病足64 例临床研究》;裴晏民;《中国当代医药》;20101031(第28期);第49，50页 * |
| 糖尿病足的中医药治疗进展;赵立沙等;《国医论坛》;20060320(第02期);第53-55页 * |
| 裴晏民.《诺迪康胶囊治疗糖尿病足64 例临床研究》.《中国当代医药》.2010,(第28期),第49-50页. * |
| 赵立沙等.糖尿病足的中医药治疗进展.《国医论坛》.2006,(第02期), * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104800425A (en) * | 2015-04-23 | 2015-07-29 | 杨孝良 | External Chinese herbal compound applying liquid for treating diabetic foot ulcer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102940677A (en) | 2013-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102940757B (en) | Medicine composition for treating diabetic foot | |
| CN102940693B (en) | Medicine composition for treating diabetic foot | |
| CN1907394B (en) | Medicine for treating diabetes foot | |
| CN102940677B (en) | Medicine composition for treating diabetic foot | |
| CN1541676A (en) | Health care medicine for enriching blood in puerperium and its preparation and uses | |
| CN102940743B (en) | Medicine composition for treating diabetic foot | |
| CN104248717B (en) | A kind of foot-bath traditional Chinese medicine composition for treating hypertension and preparation method thereof | |
| CN101716248B (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN104548029A (en) | Pharmaceutical composition for treating epigastric pain | |
| CN102940671B (en) | Medicine composition for treating diabetic foot | |
| CN104623583A (en) | Asthenia cold abdominalgia treating drug and preparation method of asthenia cold abdominalgia treating drug oral liquid | |
| CN107468857A (en) | A kind of Chinese medicinal preparation method that can treat gastric ulcer | |
| CN103798472B (en) | A kind of health protection tea and health care's preparation | |
| CN103055190B (en) | Traditional Chinese medicine preparation with liver protection and antialcoholism functions | |
| CN107496567B (en) | Traditional Chinese medicine preparation for treating diabetic foot disease and preparation method thereof | |
| CN102743468B (en) | Traditional Chinese medicine preparation for treating headache, dizziness and concussion sequelae | |
| CN104095915A (en) | Traditional Chinese medicine composition for treating diabetic foot | |
| CN103768290A (en) | Traditional Chinese medicine composition for treating synovitis and preparation method thereof | |
| CN104042916A (en) | Bitter gourd traditional Chinese medicine preparation capable of treating diabetes and preparation method thereof | |
| CN109420039A (en) | A kind of Chinese medicine treated diabetes and merge hypoglycemia | |
| CN104435167A (en) | Traditional Chinese medicine composition containing eupolyphaga for treating diabetic feet | |
| CN104435497A (en) | Traditional Chinese medicinal composition for treating diabetic feet | |
| CN101391045B (en) | Traditional Chinese medicine compound preparation for treating migraine and general headache and preparation method thereof | |
| CN107095977A (en) | A kind of medicament and its pharmaceutical formulation and preparation method with the malicious effect of fire row of dispelling | |
| CN106581468A (en) | Preparation method of traditional Chinese medicine capable of treating gastric ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141126 |